Patient Corner

Anatomical Illustrations

More

Latest drug updates

  • 31 Jul 2017 - Drug Updates

Daclizumab (Zinbryta▼) in multiple sclerosis: Review patients for liver function currently on treatment

Initiate daclizumab in restricted groups of patients with limited treatment options and closely monitor liver function.

Read more
  • 28 Jul 2017 - Drug Updates

Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): Risk of graft rejection

Consider the benefit of treatment with nivolumab or pembrolizumab versus the risk of possible organ transplant rejection for each patient.

Read more
  • 27 Jun 2017 - Drug Updates

Brimonidine gel (Mirvaso): Risk of cardiovascular events if applied to damaged skin

Advise patients not to apply brimonidine gel to irritated or damaged skin.

Read more
  • 27 Jun 2017 - Drug Updates

Restrictions to manage the risk for misuse of pseudoephedrine and ephedrine to be continued

Sale and supply of these products should be done under supervision of pharmacist or suitably trained pharmacy staff.

Read more
  • 27 Jun 2017 - Drug Updates

Yellow Card Scheme Website: Report any side effects or safety concerns with e-cigarettes and e-liquids

Information on Yellow Card Scheme Website can aid in identifying unrecognised side effects and can thereby help to support the safety of e-cigarettes.

Read more
  • 28 Jul 2017 - Drug Updates

Bendamustine (Levact): Increased mortality when used in combination treatment outside the approved indications

Closely monitor patients for opportunistic infections as well as cardiac, neurological, and respiratory adverse events.

Read more
  • 30 May 2017 - Drug Updates

Finasteride 1 mg (Propecia): Reports of depression and suicidal thoughts in men

Advise patients to discontinue treatment immediately if episodes of depressive illness and suicidal thoughts are reported.

Read more
  • 28 Apr 2017 - Drug Updates

Multiple sclerosis: Rebound syndrome after stopping fingolimod (Gilenya▼) or switching therapy

HCPs advised to report adverse effects associated with fingolimod (Gilenya▼) or other treatments for multiple sclerosis.

Read more
  • 28 Apr 2017 - Drug Updates

Valproate (Epilim▼, Depakote▼): High risk of neurodevelopmental disability and birth defects

Valproate should not be prescribed to women and girls of childbearing potential unless other treatments are ineffective or not tolerated.

Read more
  • 28 Apr 2017 - Drug Updates

Ponatinib (Iclusig▼): Risk of vascular arterial occlusion is dose-dependent

Dose reduction of ponatinib to 15 mg a day can decrease the risk of vascular arterial occlusion.

Read more